VivoSeq
Other

Blood Loss

0

Pipeline Programs↗

5

Active Trials↗

2

Companies Involved↗

Blood Loss is an early-stage landscape with 0 programs across 2 companies. The most active players are Merck & Co., Mehdi Trifa.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

90/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalM

Mehdi Trifa

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

20

clinical trials

Completed9 · 45%
Unknown status5 · 25%
Recruiting4 · 20%
Terminated1 · 5%
Enrolling by invitation1 · 5%

Clinical Trials

Trial Activity

20 trials

Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
Recruiting·—·Phase 3·NCT05744219·338 enrolled
The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Without Using Haemostatic Tourniquets
Recruiting·WWael Elbanna Clinic·N/A·NCT05266534·162 enrolled
Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy
Recruiting·—·N/A·NCT07390864·40 enrolled
Risk Factors for Homologous Blood Transfusion and Impact of Cell Saver Use in Pediatric Scoliosis Surgery: A Retrospective Monocentric Study
Recruiting·—·N/A·NCT07661589·200 enrolled
Prospective Multicenter Clinical Validation of a Novel Multifunctional Intraoperative Blood Loss Monitoring System
Enrolling by invitation·LLanzhou University Second Hospital·N/A·NCT07617428·120 enrolled
Impact of Hyperoncotic Albumin to Support Blood Loss Replacement
Completed·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT03848507·24 enrolled
Argipressin's Influence on Blood Loss During Hepatic Resection
Completed·—·Phase 4·NCT05293041·248 enrolled
Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.
Completed·—·Phase 3·NCT05024253·48 enrolled
Comparison Between Hyperoncotic and Isooncotic Albumin to Support Blood Loss Replacement
Completed·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT05391607·42 enrolled
Terlipressin Infusion During Whipple Procedure: Effect on Blood Loss and Transfusion Needs
Completed·—·Phase 2·NCT03572088·40 enrolled
Effect of Oxytocin Infusion on Blood Loss During Abdominal Myomectomy
Completed·KKanuni Sultan Suleyman Training and Research Hospital·Phase 4·NCT03308643·100 enrolled
Effect of no Drainage Tube on Blood Loss and Recovery After High Tibial Osteotomy
Completed·QQilu Hospital of Shandong University·N/A·NCT03954860·80 enrolled
The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Using Haemostatic Tourniquets:
Completed·WWael Elbanna Clinic·N/A·NCT05242783·99 enrolled
Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn
Completed·UUnited States Army Institute of Surgical Research·Phase 3·NCT00243243·20 enrolled
Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement
Terminated·Merck & Co. logoMerck & Co.·Phase 2·NCT00448864·75 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)